DName-iT has developed a unique molecular barcoding methodology and accompanying software. This genetic barcode is added to samples before sequencing, enabling each sample to be tracked throughout the entire sequencing process.
I was asked to identify market segments and determine the go-to-market strategy and market potential for NGS-based clinical oncology, clinical diagnostics for infectious diseases and the NIPT market.
To this end, I conducted a market survey among potential end users, including clinical sequencing laboratories and clinical diagnostic companies in the EU and the US, as well as key players in NIPT testing. Based on these interviews and additional desk research, I assessed the market potential, determined willingness to pay and defined the investments required for DName-iT’s continued growth.
This information was also presented to investors as part of a follow-on investment round.
Reference: Ilse Sienaert, Investment Manager Spin-off & Innovation, KU Leuven Research & Development
